Throughout Tuesday’s buying and selling session, the shares of a worldwide, research-driven pharmaceutical firm engaged in creating and manufacturing a variety of pharmaceutical merchandise surged practically 7.3 % on BSE, after the corporate introduced buying 14 ANDAs from Dr Reddy’s Laboratories.
Worth Motion
With a market cap of Rs. 2,597 crores, the shares of Senores Prescribed drugs Restricted closed within the inexperienced at Rs. 563.95 on BSE, up by round 6.3 %, as in comparison with its earlier closing value of Rs. 530.4. The inventory has delivered optimistic returns of practically 1.1 % over a one-year interval, in addition to round 6 % returns within the final one month.
What’s the Information
Senores Prescribed drugs Restricted (SPL), by way of its wholly-owned subsidiary Senores Prescribed drugs, Inc., USA, has signed agreements to amass a portfolio of 14 Abbreviated New Drug Purposes (ANDAs) from Dr. Reddy’s Laboratories and its relevant associates, in line with the most recent alternate filings.
The portfolio contains 13 ANDAs which are USFDA-approved and 1 ANDA pending USFDA approval. The addressable market alternative for the acquired ANDAs within the USA is ~$421 million (MAT December 2024) in line with IQVIA, and ~$1.13 billion (MAT September 2024) in line with specialty information aggregator Symphony.
The acquisition might be financed by way of the proceeds raised from SPL’s Preliminary Public Providing (IPO), in alignment with the goals outlined within the IPO’s Purple Herring Prospectus.
The corporate’s Managing Director commented, “These merchandise will be distributed by way of a number of/various channels, with massive necessities in authorities, retail and specialty clinics. This Portfolio of merchandise considerably will increase our merchandise providing within the US, and in addition it has a major worth in different Regulated and Semi-Regulated markets of the world.”
Additionally learn: Auto ancillary shares crashes after US President Trump imposes tariffs on Mexico & Canada
Financials
Senores Prescribed drugs reported a major development in income from operations, experiencing a year-on-year improve of practically 31 %, rising from Rs. 78.7 crores in Q3 FY24 to Rs. 103 crores in Q3 FY25.
Equally, throughout the identical interval, the corporate’s web revenue elevated from Rs. 7 crores to Rs. 16 crores, representing a powerful development of round 128.6 % YoY. EBITDA for Q3 FY25 elevated by about 92 % YoY to Rs. 29 crores, up from Rs. 15 crores in Q3 FY24, whereas the EBITDA margins grew by 810 bps to 27.3 %, from 19.2 %, over the identical interval.
In regards to the Firm
Senores Prescribed drugs Restricted is a worldwide, research-driven pharmaceutical firm centered on creating and manufacturing a variety of pharmaceutical merchandise for the US, Canada, and different regulated and rising markets throughout numerous therapeutic areas and dosage types.
The corporate makes a speciality of advanced generics, essential care injectables, and Energetic Pharmaceutical Substances (API). SPL’s Chhatral manufacturing facility is authorized by regulatory our bodies in over 10 nations, with greater than 260 product registrations and 530 product purposes.
Written by Shivani Singh
Disclaimer
The views and funding suggestions expressed by funding consultants/broking homes/ranking businesses on tradebrains.in are their very own, and never that of the web site or its administration. Investing in equities poses a threat of economic losses. Buyers should due to this fact train due warning whereas investing or buying and selling in shares. Dailyraven Applied sciences or the writer aren’t responsible for any losses triggered on account of the choice based mostly on this text. Please seek the advice of your funding advisor earlier than investing.
